Yogamet-Trio 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, reducing postprandial hyperglycemia. The sustained-release formulation ensures a gradual release of active ingredients, promoting consistent plasma concentrations and improved patient compliance. Yogamet-Trio 1 Tablet SR is indicated for use in patients inadequately controlled on diet, exercise, and monotherapy, providing a multifaceted approach to blood sugar regulation. It should be used under medical supervision, with regular monitoring of blood glucose and renal function to minimize potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis. Dose adjustments may be necessary based on therapeutic response and tolerability. This combination therapy offers a comprehensive strategy to manage hyperglycemia by targeting multiple pathophysiological defects in type 2 diabetes.